Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include ...

Hodgkin's Disease Survivors More Fatigued Than the General Population PURPOSE: Primary systemic amyloidosis is an immunoglobulin deposition disorder in which insoluble light chains cause organ ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

− First and Only FDA-approved Treatment Available in the United States for this Indication – − ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment ...

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era Ninety-four patients from ...

First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designation Follows Recent Initiation of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial of NEOD001 ...

Cardiac amyloidosis, or "stiff heart syndrome," is a rare manifestation of amyloidosis, which carries the worst prognosis of any involved organ. Researchers have developed a new technique that they ...

Please provide your email address to receive an email when new articles are posted on . Alnylam announced top-line results of a trial showing that patisiran improved 6-minute walk test distance in ...

– AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality of Life and Gait Speed Relative to External Placebo – – Company Expects to Launch in Early ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with hereditary amyloidosis and polyneuropathy, according to the results of a ...